These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 15897593)

  • 1. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
    Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
    Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
    Hofland KF; Thougaard AV; Dejligbjerg M; Jensen LH; Kristjansen PE; Rengtved P; Sehested M; Jensen PB
    Clin Cancer Res; 2005 Sep; 11(18):6722-9. PubMed ID: 16166453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
    Herman EH; Ferrans VJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.
    Imondi AR
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):22-30. PubMed ID: 9768820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
    Hasinoff BB; Yalowich JC; Ling Y; Buss JL
    Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
    Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
    Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
    Langer SW; Thougaard AV; Sehested M; Jensen PB
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):125-8. PubMed ID: 16001176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
    Lemez P; Maresová J
    Neoplasma; 1996; 43(6):417-9. PubMed ID: 8996568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
    Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
    Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
    Plandé J; Platel D; Tariosse L; Robert J
    Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.